Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNASDAQ:KYTXOTCMKTS:PVOTFNASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.54+1.6%$2.71$2.07▼$4.20$81.78M0.4389,483 shs23,656 shsKYTXKyverna Therapeutics$2.55-1.2%$2.13$1.78▼$16.64$110.21M2.17423,263 shs295,718 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsTCRXTScan Therapeutics$1.45+1.4%$1.38$1.02▼$9.29$82.06M1.06403,479 shs369,502 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-4.21%-9.42%-18.03%+3.31%KYTXKyverna Therapeutics+13.66%+7.95%+22.86%-8.77%-80.15%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%TCRXTScan Therapeutics+3.62%+18.18%-10.63%-25.13%-83.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences2.1088 of 5 stars3.63.00.00.02.21.70.0KYTXKyverna Therapeutics2.1646 of 5 stars3.63.00.00.02.51.70.0PVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ATCRXTScan Therapeutics4.0672 of 5 stars4.54.00.00.03.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00254.33% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50625.49% UpsidePVOTFBetterLife Pharma 0.00N/AN/AN/ATCRXTScan Therapeutics 3.00Buy$7.80437.93% UpsideCurrent Analyst Ratings BreakdownLatest PVOTF, ANIX, TCRX, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/8/2025TCRXTScan TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025ANIXAnixa BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/14/2025TCRXTScan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$10.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K389.43N/AN/A$0.59 per share4.31KYTXKyverna Therapeutics$7.03M15.68N/AN/AN/A∞PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ATCRXTScan Therapeutics$4.42M18.56N/AN/A$3.15 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.39N/A∞N/AN/A-58.55%-53.29%6/3/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ATCRXTScan Therapeutics-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%8/11/2025 (Estimated)Latest PVOTF, ANIX, TCRX, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/11/2025Q1 2025ANIXAnixa Biosciences-$0.10-$0.10N/A-$0.10N/AN/A3/5/2025Q4 2024TCRXTScan Therapeutics-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.548.54KYTXKyverna TherapeuticsN/A10.5010.50PVOTFBetterLife PharmaN/A3.623.62TCRXTScan Therapeutics0.139.569.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%KYTXKyverna Therapeutics18.08%PVOTFBetterLife PharmaN/ATCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%KYTXKyverna Therapeutics22.00%PVOTFBetterLife Pharma34.77%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.20 million24.05 millionOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableTCRXTScan Therapeutics10056.59 million51.90 millionNot OptionablePVOTF, ANIX, TCRX, and KYTX HeadlinesRecent News About These CompaniesTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28 at 7:00 AM | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head ContrastMay 25 at 1:13 AM | americanbankingnews.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comHead-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Twist Bioscience (NASDAQ:TWST)May 22, 2025 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comEquities Analysts Set Expectations for TCRX Q2 EarningsMay 13, 2025 | marketbeat.comWedbush Equities Analysts Cut Earnings Estimates for TCRXMay 11, 2025 | marketbeat.comResearch Analysts Issue Forecasts for TCRX Q1 EarningsMay 10, 2025 | marketbeat.comWhat Analysts Are Saying About TScan Therapeutics StockMay 10, 2025 | nasdaq.comHC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock PriceMay 9, 2025 | marketbeat.comTScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at WedbushMay 8, 2025 | marketbeat.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics (TCRX) to Release Earnings on MondayMay 7, 2025 | marketbeat.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from AnalystsMay 5, 2025 | marketbeat.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comAdage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)April 30, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%April 17, 2025 | aaii.comNeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVOTF, ANIX, TCRX, and KYTX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$2.54 +0.04 (+1.60%) Closing price 04:00 PM EasternExtended Trading$2.54 +0.00 (+0.20%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Kyverna Therapeutics NASDAQ:KYTX$2.55 -0.03 (-1.16%) Closing price 04:00 PM EasternExtended Trading$2.56 +0.01 (+0.20%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.TScan Therapeutics NASDAQ:TCRX$1.45 +0.02 (+1.40%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.02 (-1.38%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.